KRAS and lung adenocarcinoma: We extended study of epigenetic priming to a patient-derived xenograft (PDX) model of lung adenocarcinoma, LX7, which has poorly differentiated histology, is negative for KRAS, EGFR (exons 18–21), and BRAF mutations, and is negative for ALK-fusions by cytogenetic analysis.